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Abstract DNA enzymes are RNA-cleaving single-stranded
DNA molecules. We designed DNA enzymes targeting the
PB2 mRNA translation initiation (AUG) region of the in£uenza
A virus (A/PR/8/34). The modi¢ed DNA enzymes have one or
two N3P-P5P phosphoramidate bonds at both the 3P- and 5P-
termini of the oligonucleotides, which signi¢cantly enhanced
their nuclease resistance. These modi¢ed DNA enzymes had
the same cleavage activity as the unmodi¢ed DNA enzymes,
determined by kinetic analyses, and reduced in£uenza A virus
replication by more than 99%, determined by plaque formation.
These DNA enzymes are highly speci¢c; their protective e¡ect
was not observed in in£uenza B virus (B/Ibaraki)-infected Mad-
in^Darby canine kidney cells.
7 2004 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
Key words: Modi¢ed DNA enzyme;
N3P-P5P phosphoramidate oligonucleotide; In£uenza A virus;
Kinetic analysis ; Nuclease resistance; Plaque formation assay
1. Introduction
In£uenza viruses cause severe colds with generalized symp-
toms. In£uenza is a very infectious disease, and lethal pneu-
monia often develops, particularly in aged patients or high-
risk patients with chronic respiratory disorders or heart dis-
ease. The in£uenza viruses are classi¢ed into three types, A, B,
and C, on the basis of di¡erences in the serotypes of the
nucleoproteins and the membrane proteins. In£uenza virus
is a negative-strand RNA virus with a segmented genome.
Essentially all of the transcription and replication studies of
in£uenza virus have been performed with A viruses, which
contain eight virion RNA segments. Viral mRNA synthesis
is catalyzed by four viral proteins [1] : the nucleocapsid pro-
tein and the three P (PB1, PB2, and PA) proteins [2^4]. The
PB1, PB2, PA, and NP genes are potential targets for anti-
sense oligonucleotides.
We previously demonstrated that an antisense phosphoro-
thioate oligonucleotide (S-ODN-PB2-as), containing AUG in-
itiation codon sequences and targeted to PB2 of the in£uenza
A virus RNA polymerases, has highly speci¢c suppressive
activity against in£uenza A virus growth. Its activity was
superior to the antisense phosphorothioate oligonucleotides
targeted to the PA RNA polymerases in mice infected with
the in£uenza A virus [5].
Selective inactivation of a target gene by antisense mecha-
nisms is an important biologic tool to delineate the speci¢c
functions of the gene product [6^10]. Approaches mediated by
RNA-cleaving ribozymes are attractive, because of their abil-
ity to catalytically cleave the target RNA [11^14]. These mol-
ecules (both as native nucleic acids and in modi¢ed forms),
however, are highly susceptible to enzymatic hydrolysis, and
have the potential for side e¡ects in the cellular environment,
thus limiting their pharmaceutical applications in a direct de-
livery mode. Recently, a new class of catalytic molecules,
made of single-stranded DNA (deoxyribozyme or DNA en-
zyme), was obtained through in vitro selection [15^20]. One
type, the deoxyribozyme, is especially useful because of its
ability to bind and cleave any single-stranded RNA at pu-
rine/pyrimidine junctions [18]. The sequence-speci¢c cleavage
activities of short DNA molecules possessing two previously
identi¢ed catalytic motifs (10^23 and 8^17) [18] were recently
recognized as powerful biologic tools to interfere with gene
expression. The performance of DNA enzymes bearing the
10^23 motifs has been demonstrated in a number of in vivo
biologic systems [20^25]. These RNA-cleaving DNA enzymes
(DNA enzymes) are expected to be more stable than short
catalytic RNAs (ribozymes), which are inherently less stable.
DNA enzymes with natural linkages, however, are degraded
by nucleases present in serum and cells [26]. One approach to
this problem has been the development of protective modi¢-
cations of the 3P- and/or the 5P-ends of the chain, because the
primary degradation enzymes present in cells are of the 3P-
exonuclease type [27,28]. Recently, several stabilization meth-
ods for phosphodiester oligonucleotides were proposed, such
as the incorporation of various chemical substituents at the
3P-hydroxyl groups [27,28], the circularization of the oligonu-
cleotides by joining of the 3P- and 5P-ends [29,30], and the
formation of a hairpin loop structure at the 3P-end [31,32].
More recently, uniformly modi¢ed oligonucleotide N3P-P5P
phosphoramidates, in which every 3P-oxygen is replaced by
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a 3P-amino group, were synthesized by Gryaznov et al. [33,34].
These compounds have very high a⁄nity for single-stranded
RNA, and thus have potential utility as antisense agents.
In this paper, we describe the design of partially modi¢ed
DNA enzymes with N3P-P5P phosphoramidates [33] at both
the 3P- and 5P-ends. These modi¢ed DNA enzymes might have
enhanced stability against intracellular degradation by nucle-
ases [35]. We also investigated the cleavage potentials of these
novel DNA enzymes and compared their abilities to inhibit
the expression of in£uenza virus A.
2. Materials and methods
2.1. Oligonucleotides
Unmodi¢ed DNA enzymes were synthesized by Hokkaido System
Science (Sapporo, Japan). N3P-P5P Phosphoramidate-modi¢ed DNA
enzymes were synthesized by Transgenomic (South Plain¢eld, NJ,
USA). The DNA sequences of these oligonucleotides are as follows:
PB2Dz-9, 5P-TTCTTTCCAGGCTAGCTACAACGAATTGAATAT-
3P, and PB2Dz-9-I: 5P-TTCTTTCCAGGCAACATCGATCGAATT-
GAATAT-3P.
2.2. Virus and cells
Madin^Darby canine kidney (MDCK) cells were kindly provided
by K. Nerome (National Institute of Health, Tokyo, Japan). The cells
were grown as a monolayer stationary culture in modi¢ed Eagle’s
medium (MEM) supplemented with 7.5% sodium hydrogen carbon-
ate, 10% calf serum, and 20 mg/ml fungizone. In£uenza A/PR/8/34
(H1N1) virus was grown in the allantoic cavity of 10 day old embryo-
nated chicken eggs for 48 h at 35‡C. The allantoic £uid was clari¢ed
by centrifugation at 6000Ug for 15 min and stored at 380‡C.
2.3. Stability assay of N3P-P5P phosphoramidate DNA enzymes
Brie£y, each unlabeled DNA enzyme (6.6 Wg) was incubated in 90
Wl of 10% fetal bovine serum (FBS) at 37‡C, and duplicate 5 Wl
samples were removed at 0, 1, 2, 4, 8, 12, and 24 h. Immediately
upon sampling, a 295 Wl aliquot of 50 mM Tris/EDTA was added
to the 5 Wl aliquot, and a phenol/chloroform extraction was per-
formed. All of the samples from each time point were run directly
on 20% polyacrylamide gels without further puri¢cation or precipita-
tion, thus revealing all of the intact oligonucleotides and degradation
products. Densitometric analysis of gels stained with silver nitrate was
performed on an FLA-2000G image (Fuji Photo Film, Tokyo, Japan).
2.4. In vitro cleavage and kinetic analyses
To determine the cleavage activity of the DNA enzymes, a substrate
RNA (PB2 mRNA) was synthesized by Genset (France), and labeled
with £uorescein isothiocyanate (FITC) at the 5P-terminus. The se-
quence of this RNA is as follows: PB2 mRNA, 5P-FITC-AUUAU-
AUUCAAUAUGGAAAGAAUAA-3P. Cleavage was performed with
10 WM DNA enzyme and 1 WM synthetic PB2 mRNA, in 25 mM
MgCl2 and 50 mM Tris^HCl (pH 7.5), with the reactions incubated at
37‡C for 10, 20, 30, 60, or 120 min. The reactions were stopped with
50 mM EDTA, 9 M urea, and 0.1% xylene cyanol, denatured for
1 min at 95‡C, and cooled on ice. The product fragments and the
unreacted substrate in these samples were resolved by electrophoresis
on a 20% denaturing polyacrylamide gel. The extent of the reaction at
each time point was determined by densitometry of the gel image
produced through a FLA-2000G image (Fuji Photo Film).
The e⁄cacy of the DNA enzyme in vitro was determined by mea-
suring the rate of RNA cleavage under multiple turnover conditions.
Reactions were performed with 0.02 WM DNA enzyme and ¢ve di¡er-
ent concentrations of a FITC-labeled synthetic RNA substrate (0.2,
0.4, 1.0, 1.6, or 3.2 WM) with 25 mM MgCl2 in 50 mM Tris^HCl (pH
7.5), with the reactions incubated at 37‡C for 5, 10, 20, 30, 60, and
120 min. The values for kobs (derived from the slope of these time
course experiments) were used to generate a best ¢t line in a modi¢ed
Eadie^Hofstee plot (kobs versus kobs/[S]). In this expression, the values
for KM and Kcat are derived from the negative slope of the regression
line and the intercept, respectively.
2.5. Inhibition of in£uenza virus replication by modi¢ed DNA enzymes
The inhibitory e¡ect on in£uenza virus replication by the DNA
enzyme was determined with a plaque-forming assay. MDCK cells
were cultured in Dulbecco’s minimal essential medium (MEM; Sigma,
St. Louis, MO, USA) supplemented with 5% heat-inactivated FBS at
37‡C in 5% CO2. MDCK cells were plated at 2U105 cells/well in a
6 well plate and cultured for 24 h. Each DNA enzyme (¢nal concen-
tration 1, 5, and 10 WM) was transfected with the {N-[1-(2,3-dioleoyl-
oxy)propyl]-N,N,N-trimethylammonium methylsulfate (DOTAP)
transfection reagent (Roche, Indianapolis, IN, USA). After 4 h, the
MDCK cells were washed with phosphate-bu¡ered saline (PBS) and
infected with in£uenza virus A/Puerto Rico/8/34 (H1N1) or in£uenza
virus B (B/Ibaraki) at a multiplicity of infection (moi) of 0.01 at 37‡C
for 40 min. After infection, the cells were washed with PBS and
cultured in MEM containing 0.1% heat-inactivated FBS and 2 Wg/
ml of trypsin (Denka Seiken, Tokyo, Japan) for 3 days. The cells
were harvested, and the titer of the viruses was measured by a plaque
formation assay on MDCK cells after three cycles of freezing and
thawing. Con£uent MDCK cells on 6 well plates were inoculated
with serial dilutions of the viruses at 37‡C for 40 min, and then over-
laid with MEM containing 0.8% agarose, 5 Wg/ml trypsin, and 0.1%
FBS. After a 3 day incubation at 37‡C, the virus titer was calculated
from the plaques.
3. Results
3.1. Design and stability assay of N3P-P5P phosphoramidate
DNA enzymes
For e⁄cient catalysis in vivo, the length of the antisense
arms that recognize the target sequence and the use of modi-
¢ed oligonucleotides to enhance nuclease resistance in vivo are
both important. The degradation of unmodi¢ed phospho-
diester DNA enzymes in cultured cells, culture media, and
serum occurs primarily as a result of the 3P-exonuclease activ-
ity. Investigations have focused on designing more stable
DNA enzymes with phosphorothioate [25,26] or 2P-O-methyl
groups [26] at both the 5P- and 3P-ends, and with 3P,3P-linked
inverted thymidines [23,24]. In this paper, we studied the nu-
clease sensitivities of modi¢ed and unmodi¢ed DNA enzymes.
To cleave the PB2 mRNA, we targeted the translation initia-
tion region (AUG) of the in£uenza A virus (A/PR/8/34). To
confer serum nuclease resistance to the DNA enzymes, we
designed native DNA enzymes (PB2Dz-7, PB2Dz-8, and
PB2Dz-9), and modi¢ed DNA enzymes with di¡erent arm
lengths [PB2Dz-9-N and PB2Dz-9-N(*2)] with one or two
N3P-P5P phosphoramidate modi¢cations at both the 3P- and
5P-ends (Fig. 1). We previously reported that antisense phos-
phorothioate oligonucleotides targeting the AUG initiation
codon sequences of PB2 mRNA e¡ectively inhibited the in£u-
enza virus RNA polymerase activity and in£uenza virus rep-
lication in infected cells [36,37] and mice [5,38]. For compar-
ison with the active DNA enzyme, we also designed inactive
DNA enzymes, PB2Dz-9-I, PB2Dz-9-IN, and PB2Dz-9-
IN(*2) (same arm sequences as PB2Dz-9, PB2Dz-9-N, and
PB2Dz-9-N(*2) with an inverted catalytic core sequence)
[24]. We therefore prepared PB2Dz-9-M(*2), corresponding
to PB2Dz-9-N(*2), as a control modi¢ed DNA enzyme with
two 2P-O-methyl-ribonucleosides introduced at both the 3P-
and 5P-ends, according to the procedure of Warashina et al.
[26] (Fig. 1).
We analyzed the stability of the modi¢ed DNA enzymes,
PB2Dz-9-N and PB2Dz-9-N(*2), and the control modi¢ed
DNA enzyme, PB2Dz-9-M(*2), in 10% FBS (Fig. 2). The
synthetic oligonucleotides were incubated in 10% FBS for 1,
2, 4, 8, 12, and 24 h at 37‡C, and the products were analyzed
by electrophoresis on a 20% polyacrylamide gel. Signi¢cant
portions of the unmodi¢ed PB2Dz-9 were completely de-
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graded within 8 h (Fig. 2). In contrast, the modi¢ed PB2Dz-9-
N and PB2Dz-9-N(*2), and the control modi¢ed oligonucleo-
tide, PB2Dz-9-M(*2), remained even after a 24 h incubation.
PB2Dz-9-M(*2), however, was signi¢cantly less stable than
the N3P-P5P phosphoramidate-modi¢ed DNA enzymes. The
PB2Dz-9-N and PB2Dz-9-N(*2) enzymes had substantially
greater stability in serum as compared with the unmodi¢ed
DNA enzyme, PB2Dz-9.
3.2. Cleavage activity of DNA enzymes for the PB2 mRNA
substrate
Before examining the DNA enzymes in cells, we investi-
gated their cleavage activity against the PB2 mRNA substrate
in vitro. To determine whether the DNA enzyme cleaved
RNA, we synthesized a substrate composed of 25 nucleotides,
including the PB2 mRNA translation initiation region. Reac-
tions were performed in 50 mM Tris^HCl (pH 7.5) and 25
mM MgCl2 under single turnover conditions at 37‡C. The
unmodi¢ed DNA enzymes [PB2Dz-7 (7-mer), PB2Dz-8
(8-mer), and PB2Dz-9 (9-mer)] and the modi¢ed DNA en-
zymes [PB2Dz-9-N, PB2Dz-9-N(*2), and PB2Dz-9-M(*2)]
cleaved the 25 nucleotide RNA (labeled with FITC at the
5P-end) (Fig. 3A,B). The 13 nucleotide product was consistent
with the distance between the A28^U29 junction and the
5P- (FITC-labeled) end of the substrate. The longer-armed
DNA enzyme (PB2Dz-9) had more powerful cleavage activity
than the corresponding shorter-armed DNA enzymes
(PB2Dz-7 and 8) (Fig. 3A). Furthermore, the modi¢ed
DNA enzymes [PB2Dz-9-N, PB2Dz-9-N(*2), and PB2Dz-9-
M(*2)] also exhibited strong cleavage activity (Fig. 3B). In
contrast, the inactive DNA enzymes [PB2Dz-9-I, PB2Dz-9-
IN, and PB2Dz-9-IM(*2)] did not catalyze the release of the
Fig. 1. A schematic representation of DNA enzymes with 9U9 arms, modi¢ed at both the 5P- and 3P-ends. A DNA enzyme can be targeted to
cleave the phosphodiester bonds between a selected unpaired purine and a paired pyrimidine by virtue of the nucleotide sequences in its 5P and
3P arms. The ¢gure shows the DNA enzyme targeting the translation start site of the in£uenza A virus, PB2 mRNA. The antisense deoxyribo-
oligonucleotide (PB2-as-N) was targeted to the translation start site of the in£uenza A virus, PB2 mRNA. Its N3P-P5P phosphoramidate-modi-
¢ed derivatives include: N, N3P-P5P phosphoramidate-substituted residues, and N(*2), two N3P-P5P phosphoramidate-substituted residues;
M(*2), two 2P-O-methyl-substituted residues; I, inverted catalytic domain; as, antisense oligonucleotide.
Fig. 2. Stability assay of the modi¢ed DNA enzymes in FBS. DNA
enzymes were incubated in 10% FBS. Samples were collected at dif-
ferent time points as indicated, and the products were analyzed by
electrophoresis on a 20% polyacrylamide gel. Densitometric analysis
of gels stained with silver nitrate was performed on a FLA-2000G
image (Fuji Photo Film).
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cleavage product (P) (Fig. 3C). To further characterize the
modi¢ed DNA enzymes, we determined their kinetic parame-
ters for cleavage of the PB2 mRNA substrate under multiple
turnover conditions.
The overall catalytic e⁄ciency of each deoxyribozyme, as
measured by the Kcat/KM values, varied signi¢cantly between
the modi¢ed and unmodi¢ed species. The activities of the
unmodi¢ed DNA enzymes (PB2Dz-7, PB2Dz-8, and PB2Dz-
9) were remarkably sensitive to the length of the substrate-
binding arms (Table 1) [26,39]. In the case of the longer-
armed DNA enzymes (PB2Dz-9), which have two additional
nucleotides in their binding arms as compared with the short-
er variants, the longer binding arms yielded higher Kcat/KM
values [39]. On the other hand, a comparison of the kinetic
parameters revealed no signi¢cant di¡erences in the Kcat/KM
values between the modi¢ed and unmodi¢ed DNA enzymes
(Table 1). Therefore, we performed an in vivo assay using the
modi¢ed DNA enzymes [PB2Dz-9-N and PB2Dz-9-N(*2),
and PB2Dz-9-M(*2)], because of their similar kinetic param-
eters to those of the unmodi¢ed DNA enzyme (PB2Dz-9) and
their nuclease resistance in the subsequent anti-in£uenza ac-
tivity studies.
3.3. Comparison of the anti-in£uenza activities and speci¢cities
of modi¢ed DNA enzymes in in£uenza virus A-infected
MDCK cells
The in vivo antiviral activities of the unmodi¢ed and modi-
¢ed DNA enzymes were assessed on the basis of their inhib-
itory e¡ects on the in£uenza virus A titer. We compared the
e⁄cacies of PB2Dz-9-N, PB2Dz-9-N(*2), and PB2Dz-9-
M(*2), as representative DNA enzymes, together with the in-
active DNA enzymes with inverted catalytic domains [PB2Dz-
9-IN and PB2Dz-9-IM(*2)] and the antisense oligonucleotide
(PB2-as-N) with one N3P-P5P phosphoramidate modi¢cation
at both the 3P- and 5P-ends, by examining the virus titer of A/
PR/8/34-infected MDCK cells. In the reactions with the inac-
tive DNA enzymes, PB2Dz-9-I, PB2Dz-9-IN, and PB2Dz-9-
IM(*2), there was no cleavage activity, even when the enzymes
were incubated with the substrate for 120 min (Fig. 3C). We
used these as the inactive DNA enzymes in subsequent stud-
ies. The inhibition of in£uenza virus replication (virus titer) by
DNA enzymes was determined with a plaque-forming assay
on MDCK cells.
Inhibition experiments were performed with two di¡erent
DNA enzymes, and the results of one set of experiments are
summarized in Fig. 4. The concentration of DOTAP used in
these experiments had no cellular toxicity. The DOTAP/oli-
gonucleotide complex (67 Wg/ml/10 WM oligo) was delivered
daily for 10 consecutive days, and produced no toxicity. The
DOTAP-encapsulated PB2Dz-9-N and PB2Dz-9-N(*2) oligo-
nucleotides both suppressed in£uenza virus (A/PR/8/34) ex-
pression in MDCK cells with extremely high e⁄cacy
(s 99% inhibition). The control modi¢ed DNA enzyme,
PB2Dz-9-M(*2), had a slightly lower inhibitory e¡ect (84%)
than PB2Dz-9-N and PB2Dz-9-N(*2) in the in£uenza virus
(A/PR/8/34)-infected cells. When the controls, including the
modi¢ed inactive DNA enzymes with one or two N3P-P5P
phosphoramidates at both the 3P- and 5P-ends [PB2Dz-9-IN
and PB2Dz-9-IN(*2)] and the 2P-O-methyl-substituted ribonu-
cleoside derivative DNA enzyme, PB2Dz-IM(*2), were trans-
Fig. 3. Cleavage activity and speci¢city of the DNA enzymes in vitro. The unmodi¢ed (A) and modi¢ed (B) DNA enzymes. Inactive DNA en-
zymes (C). The substrate RNA, with the sequence 5P-FITC-AUUAUAUUCAAUAUGGAAAGAAUAA-3P, was cleaved by all three DNA en-
zymes (PB2Dz-7, 8, and 9) to generate a single product (P). The DNA enzyme (1 WM) and the synthetic PB2 mRNA (0.1 WM) were incubated
at 37‡C for the indicated times in 25 mM MgCl2 and 50 mM Tris^HCl (pH 7.5). The reactions were stopped with 50 mM EDTA, 9 M urea,
and 0.1% xylene cyanol, denatured for 1 min at 95‡C, and cooled on ice. Each reaction mixture was then subjected to electrophoresis on an
18% polyacrylamide/7 M urea gel.
Table 1
Kinetic parameters of PB2 mRNA substrate cleavage
DNA enzyme Kcat (min31) KM (WM) Kcat/KM (WM31 min31)
PB2Dz-7 1.5U1031 8.5U1031 1.8U1031 ( T 0.021)
PB2Dz-8 3.2U1031 6.0U1031 5.3U1031 ( T 0.049)
PB2Dz-9 1.1 1.2 9.2U1031 ( T 0.41)
PB2Dz-9-N 6.9U1031 4.2U1031 1.6 ( T 0.21)
PB2Dz-9-N(*2) 7.0U1031 6.7U1031 1.0 ( T 0.62)
PB2Dz-9-M(*2) 2.9U1031 3.4U1031 8.5U1031 ( T 0.33)
Rate constants were measured with 25 mM MgCl2 and 50 mM
Tris^HCl (pH 7.5) under enzyme-saturating (multiple turnover) con-
ditions at 37‡C. Rate constants are averages of results from two
sets of experiments.
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fected with the DOTAP transfection reagent, the inactive
DNA enzymes also had inhibitory e¡ects (58%, 49%, and
22%) on the replication of in£uenza virus (A/PR/8/34). The
protective e¡ect of the modi¢ed DNA enzymes [PB2Dz-9-N
and PB2Dz-9-N(*2)], however, was not observed in the in£u-
enza B virus, B/Ibaraki-infected MDCK cells (Fig. 4A). The
nucleotide sequence identity between the PB2 mRNAs of the
in£uenza A and B viruses is very low. Furthermore, the in£u-
enza virus (A/PR/8/34)-infected MDCK cells were treated
with 1 WM, 5 WM, and 10 WM each of PB2Dz-9-N(*2) for 3
days (Fig. 4B). As expected, the N3P-P5P phosphoramidate-
modi¢ed DNA enzymes inhibited replication of the in£uenza
virus (A/PR/8/34) in a dose-responsive manner.
We also examined the e¡ect of the modi¢ed antisense oli-
gonucleotide (PB2-as-N) with one N3P-P5P phosphoramidate
at both the 3P- and 5P-ends. The PB2-as-N had highly inhib-
itory e¡ects, similar to those of the S-ODN-PB2 in the in£u-
enza virus (A/PR/8/34)-infected MDCK cells (Fig. 4A) [36,37].
The inhibitory e¡ects of these modi¢ed DNA enzymes
[PB2Dz-9-N and PB2Dz-9-N(*2)], however, were higher
than that of the antisense oligonucleotide (PB2-as-N) (Fig.
4A).
4. Discussion
In£uenza virus infection has the potential to become a
much more dangerous disease than at present, because of
easy transmission, antigenic shift, and viral drift, as well as
the limited e⁄cacy of current vaccines and therapies [40]. We
demonstrated that modi¢ed DNA enzymes possess potent
anti-in£uenza activity and confer signi¢cant protection to
host cells challenged with in£uenza virus.
The in vivo antiviral activities of the new modi¢ed DNA
enzymes were assessed on the basis of their inhibitory e¡ects
on the replication of in£uenza virus A. We designed DNA
enzymes that have one or two N3P-P5P phosphoramidate
modi¢cations at both the 3P- and 5P-ends [33] (Fig. 1). We
also designed DNA enzymes with inverted catalytic domains
[PB2Dz-9-IN and PB2Dz-9-IN(*2)] [33], and with two 2P-O-
methyl-ribonucleosides [PB2Dz-9-M(*2)] at both the 3P- and
5P-ends [26] (Fig. 1).
We ¢rst studied the nuclease sensitivities of the modi¢ed
and unmodi¢ed DNA enzymes. The use of one or two N3P-
P5P phosphoramidate [PB2Dz-9-N and PB2Dz-9-N(*2)], or
2P-O-methyl-substituted residues [PB2Dz-9-M(*2)] at the 5P-
and 3P-ends signi¢cantly enhanced the nuclease resistance.
Consistent with an earlier report [26], the modi¢ed DNA en-
zyme with the 2P-O-methyl-substitution [PB2Dz-9-M(*2)] was
less nuclease-resistant than the modi¢ed DNA enzyme with
the N3P-P5P phosphoramidate.
We then investigated the cleavage activity against the PB2
mRNA substrate in vitro. The cleavage activity of the un-
modi¢ed DNA enzymes was dependent on the length of the
substrate-binding arms (Fig. 3A). Furthermore, the modi¢ed
DNA enzymes [PB2Dz-9-N, PB2Dz-9-N(*2), and PB2Dz-9-
M(*2)] also cleaved the 25 nucleotide substrate with a PB2
mRNA translation initiation region (Fig. 3B). On the other
hand, the inactive DNA enzymes [PB2Dz-9-I, PB2Dz-9-IN,
and PB2Dz-9-IM(*2)] had no cleavage activity (Fig. 3C). Fur-
thermore, we determined the kinetic parameters for the cleav-
age of the PB2 mRNA substrate under multiple turnover
conditions. The activities of the unmodi¢ed DNA enzymes
(PB2Dz-7, PB2Dz-8, and PB2Dz-9) were remarkably sensitive
to the length of the substrate-binding arms (Table 1). Com-
parisons of the kinetic parameters revealed no signi¢cant dif-
ferences in the Kcat/KM values between the unmodi¢ed and
modi¢ed DNA enzymes (Table 1). From the above results,
we selected the modi¢ed DNA enzymes [PB2Dz-9-N and
PB2Dz-9-N(*2), and PB2Dz-9-M(*2)], with higher cleavage
activity and nuclease resistance, for the subsequent anti-in£u-
enza activity studies [38]. As the control oligonucleotides, we
used the inactive DNA enzymes with inverted catalytic do-
Fig. 4. Inhibition of in£uenza virus replication by modi¢ed DNA enzymes and antisense oligonucleotides. A: MDCK cells were transfected
with a 10 WM concentration of either the DOTAP-encapsulated modi¢ed DNA enzymes or the antisense oligonucleotide (PB2-as-N), and in-
fected with in£uenza virus A (A/PR/8/34) and in£uenza virus B (B/Ibaraki) at an moi of 0.01. B: The in£uenza virus (A/PR/8/34)-infected
MDCK cells were treated with 1 WM, 5 WM, and 10 WM each of the DOTAP-encapsulated PB2Dz-9-N(*2). The inhibitory e¡ect (virus titer)
on in£uenza virus replication by the DNA enzyme was determined with a plaque-forming assay on MDCK cells.
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mains [PB2Dz-9-IN, PB2Dz-9-IN(*2), and PB2Dz-9-IM(*2)]
and the antisense oligonucleotide (PB2-as-N) with one N3P-
P5P phosphoramidate modi¢cation at both the 3P- and 5P-
ends. The modi¢ed PB2Dz-9-N and PB2Dz-9-N(*2) enzymes
suppressed the in£uenza virus expression (A/PR/8/34) in
MDCK cells with extremely high e⁄cacy (s 99% inhibition)
(Fig. 4A). Although the control modi¢ed DNA enzyme,
PB2Dz-9-M(*2), was also very active, its activity was lower
than that of PB2Dz-9-N and PB2Dz-9-N(*2) (Fig. 4A). The
protective e¡ect of these modi¢ed DNA enzymes, however,
was not observed in in£uenza B virus, B/Ibaraki-infected
MDCK cells (Fig. 4A). On the other hand, the control modi-
¢ed inactive DNA enzymes [PB2Dz-9-IN and PB2Dz-9-
IN(*2), and PB2Dz-9-IM(*2)] also had inhibitory e¡ects
(22^58%) (Fig. 4A). This is because these DNA enzymes in-
clude antisense sequences that bind to their target mRNA.
Therefore, we also examined the e¡ect of the modi¢ed anti-
sense oligonucleotide (PB2-as-N) with one N3P-P5P phosphor-
amidate at both the 3P- and 5P-ends. The modi¢ed PB2-as-N
inhibited in£uenza virus A replication in the in£uenza virus
(A/PR/8/34)-infected MDCK cells (Fig. 4A). These results
suggest that the modi¢ed DNA enzymes might be capable
of inducing a conventional antisense e¡ect.
In conclusion, in£uenza virus A PB2 mRNA can be inhib-
ited by partially modi¢ed DNA enzymes. These DNA en-
zymes exhibited higher e⁄cacy than the antisense oligonucleo-
tides. Among the limited modi¢cations that we introduced,
the N3P-P5P phosphoramidates appeared to be the most e¡ec-
tive, because the introduction of one or two such modi¢ca-
tions at each end of the DNA enzyme (PB2Dz-9-N) resulted
in signi¢cant nuclease resistance without loss of speci¢city. In
contrast, the 2P-O-methyl-substituted version of the same
DNA enzyme [PB2Dz-9-M(*2)] had no inhibitory e¡ect, de-
spite the increased nuclease resistance. The DNA enzymes are
easier to synthesize and are more stable in vivo than ribo-
zymes. The appropriately modi¢ed DNA enzymes possess po-
tent anti-in£uenza activity and confer signi¢cant protection to
host cells challenged with in£uenza virus.
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